FDA approval of Casgevy and Lyfgenia: a dual breakthrough in gene therapies for sickle cell disease-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

FDA approval of Casgevy and Lyfgenia: a dual breakthrough in gene therapies for sickle cell disease

Published:2024-07-25 Issue:9 Volume:86 Page:4966-4968
ISSN:2049-0801
Container-title:Annals of Medicine & Surgery
language:en
Short-container-title:

Author:

Rahmat Zainab Syyeda¹,Ali Mohammad Haris²,Talha Muhammad²,Hasibuzzaman Md. Al³

Affiliation:

1. Faculty of Medicine, Dow Medical College, Dow University of Health Sciences, Karachi

2. Shaikh Khalifa Bin Zayed Al-Nahyan Medical and Dental College, Lahore, Pakistan

3. Institute of Nutrition and Food Science, University of Dhaka, Dhaka, Bangladesh

Publisher

Ovid Technologies (Wolters Kluwer Health)

Reference9 articles.

1. l-glutamine, crizanlizumab, voxelotor, and cell-based therapy for adult sickle cell disease: hype or hope?;Leibovitch;Blood Rev,2022

2. Global burden of sickle cell anaemia in children under five, 2010–2050: modelling based on demographics, excess mortality, and interventions;Piel;PLoS Med,2013

3. A network model to predict the risk of death in sickle cell disease;Sebastiani;Blood,2007

4. Sickle cell disease and psychosocial well-being: comparison of patients with preclinical and clinical avascular necrosis of the femoral head;Tezol;Turk Arch Pediatr,2021

5. Optimizing hydroxyurea therapy for sickle cell anemia;Ware;Hematol Am Soc Hematol Educ Program,2015

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP